What Biocrucible does

Biocrucible is a privately-held diagnostics company developing next-generation diagnostic products grounded in advances in biomolecular condensate formation. The company's stated proposition centers on leveraging condensate-based chemistry as a differentiated platform for diagnostic applications, a deep-tech approach that contrasts with conventional antibody- or nucleic-acid-based assay architectures. Founded in 2018, the company operates with a headcount in the 11–50 range, consistent with an early-to-mid stage research and development organization that has not yet reached scale commercialization.

The company is headquartered in Cambridge, listed in the input as United States (noting that its registered web domain is biocrucible.co.uk, which is consistent with a UK corporate presence and may indicate a transatlantic structure or a data-entry discrepancy). Leadership comprises David Brooks as Chief Executive Officer and Niall Armes as Chief Scientific Officer, suggesting a lean founder-led operating model in which scientific direction and executive oversight sit with two named individuals. No products, customers, partnerships, funding rounds, regulatory milestones, or revenue figures specific to Biocrucible are disclosed in the available source material; the bulk of the operational data aggregated alongside Biocrucible's firmographics pertains to Sapphiros (a separate diagnostics platform company with Roche, BARDA, NIH, Gates Foundation, and KKR relationships and a 5-billion-unit manufacturing footprint) and is therefore not attributable to Biocrucible for analytical purposes. As a result, the business model, go-to-market motion, customer segmentation, and unit economics for Biocrucible cannot be characterized from the present evidence base and represent a material information gap for any prospective investor or acquirer.

Name

Biocrucible

Website

https://biocrucible.co.uk

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Biocrucible is a privately-held, Cambridge-based diagnostics company founded in 2018 that is developing next-generation diagnostic tests based on proprietary advances in biomolecular condensate formation. It operates with 11–50 employees and is led by CEO David Brooks and CSO Niall Armes.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL)

akta.pro secondary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Biomolecular condensate diagnostics
• Molecular diagnostic assays
• Diagnostic platform development
• Protein condensate detection
• Clinical biomarker discovery

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Diagnostic Test Products: Sale of molecular, lateral flow, and digital diagnostic test products across multiple platforms. Large-scale supply agreements with major healthcare partners.
2. Manufacturing Services: Extreme volume manufacturing capabilities providing capacity for pandemic preparedness and emergency response testing.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Biocrucible is developing next-generation diagnostics based upon breakthrough advances in biomolecular condensate formation. The company is leveraging novel biomolecular condensate science to create advanced molecular diagnostic capabilities, building a proprietary technology platform aimed at clinical and research diagnostic applications.

Product overview

Sapphiros offers a multi-platform diagnostic product portfolio comprising four core product categories: Handheld 1-step Molecular, Digital Lateral Flow, Blood Collection & Detection, and Lateral Flow tests. These are supported by four key manufacturing and technology capabilities: Extreme Volume Manufacturing (with 5 billion unit capacity), Visual Lateral Flow, Printed Electronics, and In-house molecular reagents. The company focuses on delivering low-cost, easy-to-use, scalable diagnostics for consumer health applications with laboratory-quality accuracy.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 5 billion unit annual manufacturing capacity
• +1 more outcomes

Named customers4 records

Segments3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core and flagship.

• BARDA (Biomedical Advanced Research and Development Authority)coreStrategic or Co-development Partner · 1 December 2025BARDA announced collaboration with Sapphiros for development of an OTC, single-use, low-cost digital antigen test that can detect and differentiate between respiratory viruses. This government partnership supports public health emergency preparedness.
• RocheflagshipStrategic or Co-development Partner · 19 November 2025Strategic agreement providing Roche access to 1 billion lateral flow tests annually and access to future molecular point-of-care tests. Agreement secures rapid, global access to tests for future pandemics and health emergencies. Under the agreement, Roche gains access to at least 1 billion tests annually from Sapphiros' 5 billion unit capacity proprietary manufacturing process.
• Gates FoundationcoreStrategic or Co-development PartnerListed as trusted partner supporting global health initiatives and access to diagnostics for underserved populations worldwide.
• National Institutes of Health (NIH)coreStrategic or Co-development PartnerListed as trusted government partner for diagnostic development and healthcare research initiatives.
• OraSure TechnologiescoreStrategic or Co-development PartnerListed as trusted partner in the diagnostics ecosystem, providing complementary capabilities in testing technologies.

Scale indicators3 records

Direct peers

• SomaLogic: Protein biomarker measurement company using aptamer-based binding assays for high-throughput proteomics. Comparable in translating a novel molecular-recognition approach into a commercial proteomics platform.
• Olink: Provider of high-multiplex protein biomarker analytics (Proximity Extension Assay) for pharma services and diagnostics. Relevant peer because it monetized a novel protein-detection biophysics via kit sales and partnerships.
• Quanterix: Developer of ultra-sensitive protein biomarker detection platforms (Simoa) for research and diagnostics. Comparable because both operate in next-generation protein-based diagnostic detection where novel biophysics could translate to differentiated performance.

Emerging players

• 10x Genomics: Single-cell and spatial molecular biology tools that bridge research and clinical diagnostics. Comparable as a life science tools company commercializing a novel platform technology into diagnostics-adjacent markets.
• Nautilus Biotechnology: Single-molecule protein analysis platform aiming to characterize the proteome comprehensively. Comparable as an early-stage platform company pursuing a fundamentally different biophysical modality for protein characterization.

Broad incumbents

• Bio-Techne: Large life science tools and diagnostics supplier with proteomics, immunoassay, and diagnostic reagent product lines. Relevant as a potential strategic acquirer / channel partner for novel protein-based diagnostic platforms.
• Standard BioTools: Life science tools company with protein and genomic analysis platforms for research and clinical markets. Comparable as a multi-modality tools/diagnostics vendor where novel assay platforms could be integrated or acquired.
• Sapphiros: Multi-platform diagnostics company (molecular, lateral flow, digital) with large-scale manufacturing and global healthcare partnerships. Closely associated with Biocrucible in the source data and represents the broader consumer/professional diagnostics space Biocrucible's platform could plug into.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocrucible